Telfast - 30mg / 5 ml Suspension 100 ml

Elimination of symptoms associated with urticaria in children from 6 months of age; symptoms of seasonal allergic rhinitis (SAR) from 2 years of age.

Trade name: Telfast

Telfast

Composition: Each 5 ml of suspension contains 30 mg of fexofenadine hydrochloride.

Auxiliary components: propylene glycol, disodium edetate, propyl hydroxybenzoate, butyl hydroxybenzoate, xanthan gum, poloxamer 407, titanium dioxide, monobasic sodium phosphate monohydrate, dibasic sodium phosphate heptahydrate, raspberry flavor and purified water, xylitol.

Pharmacological group:

Antiallergic agent.

Properties: Telfast is an antihistamine drug that is an antagonist of histamine H-1 receptors. Does not sedate or otherwise affect the central nervous system. The antiallergic effect appears after 1 hour, after a maximum of 6 hours, continues to act for 24 hours.

Indications: elimination of symptoms associated with urticaria in children from 6 months of age; symptoms of seasonal allergic rhinitis (SAR from 2 years of age.

Mode of application: Urticaria: from 6 months up to 2 years — 15 mg

(2.5 ml) 2 r/ d. Children from 2 to 11 years old — 30mg (5ml) 2 r/ d (with reduced renal function from 6 months to 11 years, 1 time per day).

With symptoms of SAR: children from 2 to 11 years old — 30 mg 2 times a day (with reduced renal function 1 r / day). Shake the bottle well before each use.

Contraindications: hypersensitivity to fexofenadine, terfenadine or other components of the drug.

Side effects: Fexofenadine is generally well tolerated. The most common (1-10% of cases) reported headache, fatigue, dizziness or drowsiness, and nausea. In placebo-controlled studies with a frequency of less than 1%, weakness, insomnia, nervousness, sleep disturbance, tachycardia, palpitations, and diarrhea were noted. In rare cases (less than 0.1%), exanthema, urticaria, itching, Quincke’s ede shortness of breath, shortness of breath,

reddening of the skin, anaphylactic reactions were observed.

Pregnancy Category B:

There are no adequate and well-controlled studies in pregnant women. Fexofenadine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation: there are no data on the content of fexofenadine in breast milk when it is taken by breastfeeding women. Its penetration into breast milk was observed. The use of fexofenadine during breastfeeding is not recommended.

Precautions: do not exceed the recommended dose of the drug. Do not drink fruit juices at the same time as fexofenadine: grapefruit, orange and apple may reduce its effectiveness.

Storage: Store at room temperature, in a dry place out of reach of children.

Packaging: 100 ml bottle and paper instructions.